Immunotherapy for neuromyelitis optica spectrum disorder: a comparative analysis of efficacy and safety of azathioprine, mycophenolate mofetil, tacrolimus, and rituximab
The study provides data comparing the efficacy of various off-label treatments in a Chinese NMOSD cohort, illustrating that RTX is more effective than traditional immunosuppressants in controlling NMOSD relapses and disease activity but no superiority in the time to the first relapse post-immunotherapy initiation. RTX and MMF may offer superior treatment alternatives for NMOSD patients compared to TAC and AZA.
Authors
- Jing Zhou (ORCID: https://orcid.org/0000-0003-1774-085X)
- Xiaolin Yang (ORCID: https://orcid.org/0000-0001-9900-528X)
- Haoran Zhang (ORCID: https://orcid.org/0000-0002-7059-572X)
- Xinyi Wang (ORCID: https://orcid.org/0000-0001-7527-838X)
- Yi Zhu (ORCID: https://orcid.org/0000-0003-0288-5554)
- Bin Li (ORCID: https://orcid.org/0000-0002-8607-8874)
- Yun Xu
- Xiaoming Wang
- Jinzhou Feng
Institutions
- North Sichuan Medical University (CN)
- Jinan University (CN)
- Capital Medical University (CN)
- Beijing Tian Tan Hospital (CN)
- Affiliated Hospital of North Sichuan Medical College (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-04-28
- DOI
- https://doi.org/10.3389/fneur.2025.1559118
- Citations
- 3
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.41